LT3525B - Composition for ophthalmic use - Google Patents

Composition for ophthalmic use Download PDF

Info

Publication number: LT3525B
Authority: LT; Lithuania
Prior art keywords: composition; cyclodextrin; buffers; bispilocarpate; viscosity
Prior art date: 1993-06-24

Application number

LTIP1970A

Other languages

English (en)

Lithuanian (lt)

Inventor

Arto Urtti

Tomi Jaervinen

Pekka Suhonen

Kari Lehmussaari

Timo Reunamaeki

Sakari Alaranta

Olli Oksala

Esko Pohjala

Hannu Hanhijaervi

Original Assignee

Leiras Oy

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-06-24

Filing date

1994-06-23

Publication date

1995-11-27

1994-06-23 Application filed by Leiras Oy filed Critical Leiras Oy

1995-01-31 Publication of LTIP1970A publication Critical patent/LTIP1970A/xx

1995-11-27 Publication of LT3525B publication Critical patent/LT3525B/lt

Links

239000000203 mixture Substances 0.000 title claims abstract description 68
229920000858 Cyclodextrin Polymers 0.000 claims abstract description 63
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 44
239000002253 acid Substances 0.000 claims abstract description 15
150000005690 diesters Chemical class 0.000 claims abstract description 12
239000007864 aqueous solution Substances 0.000 claims abstract description 9
230000002708 enhancing effect Effects 0.000 claims abstract description 6
-1 1,4-xylylene Chemical group 0.000 claims description 24
239000000872 buffer Substances 0.000 claims description 13
125000000217 alkyl group Chemical group 0.000 claims description 9
229940097362 cyclodextrins Drugs 0.000 claims description 7
239000003795 chemical substances by application Substances 0.000 claims description 5
URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 claims description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
229920001661 Chitosan Chemical class 0.000 claims description 3
239000007979 citrate buffer Substances 0.000 claims description 3
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
230000000699 topical effect Effects 0.000 claims description 3
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical class CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 2
229920002307 Dextran Chemical class 0.000 claims description 2
229920002125 Sokalan® Chemical class 0.000 claims description 2
239000008351 acetate buffer Substances 0.000 claims description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical class [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
125000002252 acyl group Chemical group 0.000 claims description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
239000001768 carboxy methyl cellulose Chemical class 0.000 claims description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
239000000644 isotonic solution Substances 0.000 claims description 2
229920000609 methyl cellulose Chemical class 0.000 claims description 2
239000001923 methylcellulose Chemical class 0.000 claims description 2
235000010981 methylcellulose Nutrition 0.000 claims description 2
239000008363 phosphate buffer Substances 0.000 claims description 2
229920002451 polyvinyl alcohol Chemical class 0.000 claims description 2
235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
239000001267 polyvinylpyrrolidone Chemical class 0.000 claims description 2
229920000036 polyvinylpyrrolidone Chemical class 0.000 claims description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
229920001027 sodium carboxymethylcellulose Chemical class 0.000 claims description 2
150000007513 acids Chemical class 0.000 claims 1
125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 1
239000003002 pH adjusting agent Substances 0.000 abstract 1
238000011200 topical administration Methods 0.000 abstract 1
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical class C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 25
QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 23
229960001416 pilocarpine Drugs 0.000 description 23
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
239000000243 solution Substances 0.000 description 18
239000003814 drug Substances 0.000 description 16
229940079593 drug Drugs 0.000 description 14
150000001875 compounds Chemical class 0.000 description 12
229940002612 prodrug Drugs 0.000 description 11
239000000651 prodrug Substances 0.000 description 11
239000004480 active ingredient Substances 0.000 description 10
239000002243 precursor Substances 0.000 description 10
239000004615 ingredient Substances 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 9
238000010521 absorption reaction Methods 0.000 description 8
230000000052 comparative effect Effects 0.000 description 8
206010015946 Eye irritation Diseases 0.000 description 7
231100000013 eye irritation Toxicity 0.000 description 7
239000012530 fluid Substances 0.000 description 6
239000001116 FEMA 4028 Substances 0.000 description 5
206010027646 Miosis Diseases 0.000 description 5
229960004853 betadex Drugs 0.000 description 5
210000004087 cornea Anatomy 0.000 description 5
230000000694 effects Effects 0.000 description 5
210000003560 epithelium corneal Anatomy 0.000 description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
230000003547 miosis Effects 0.000 description 5
238000009472 formulation Methods 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
230000007794 irritation Effects 0.000 description 4
230000021121 meiosis Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
125000000732 arylene group Chemical group 0.000 description 3
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 3
125000002993 cycloalkylene group Chemical group 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
238000006386 neutralization reaction Methods 0.000 description 3
QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000001070 adhesive effect Effects 0.000 description 2
125000002947 alkylene group Chemical group 0.000 description 2
210000002159 anterior chamber Anatomy 0.000 description 2
235000011175 beta-cyclodextrine Nutrition 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
238000010668 complexation reaction Methods 0.000 description 2
125000005724 cycloalkenylene group Chemical group 0.000 description 2
125000000753 cycloalkyl group Chemical group 0.000 description 2
230000007423 decrease Effects 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
239000003925 fat Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
241000208202 Linaceae Species 0.000 description 1
235000004431 Linum usitatissimum Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001490213 Milium Species 0.000 description 1
201000002481 Myositis Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000232219 Platanista Species 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
230000004308 accommodation Effects 0.000 description 1
239000003732 agents acting on the eye Substances 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000004450 alkenylene group Chemical group 0.000 description 1
125000004419 alkynylene group Chemical group 0.000 description 1
229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000002585 base Substances 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
229910021538 borax Inorganic materials 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000007073 chemical hydrolysis Effects 0.000 description 1
229960003260 chlorhexidine Drugs 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
230000001886 ciliary effect Effects 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
210000000871 endothelium corneal Anatomy 0.000 description 1
230000007071 enzymatic hydrolysis Effects 0.000 description 1
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
210000005081 epithelial layer Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000004438 eyesight Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000446 fuel Substances 0.000 description 1
GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
229940023490 ophthalmic product Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000003223 protective agent Substances 0.000 description 1
230000004478 pupil constriction Effects 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000000344 soap Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000010339 sodium tetraborate Nutrition 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
150000003871 sulfonates Chemical class 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229960004906 thiomersal Drugs 0.000 description 1
230000032258 transport Effects 0.000 description 1
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000009278 visceral effect Effects 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Nanotechnology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Ophthalmology & Optometry (AREA)
General Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Molecular Biology (AREA)
Crystallography & Structural Chemistry (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

LTIP1970A 1993-06-24 1994-06-23 Composition for ophthalmic use LT3525B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE9302203A SE501482C2 (sv)	1993-06-24	1993-06-24	Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning

Publications (2)

Publication Number	Publication Date
LTIP1970A LTIP1970A (en)	1995-01-31
LT3525B true LT3525B (en)	1995-11-27

Family

ID=20390417

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTIP1970A LT3525B (en)	1993-06-24	1994-06-23	Composition for ophthalmic use

Country Status (5)

Country	Link
AU (1)	AU6973194A (et)
EE (1)	EE9400040A (et)
LT (1)	LT3525B (et)
SE (1)	SE501482C2 (et)
WO (1)	WO1995000144A1 (et)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0777415A4 (en) *	1994-07-11	1999-06-16	David W Pate	COMPOSITIONS CONTAINING AN ANANDAMIDE ANALOG AND METHOD FOR TREATING INCREASED EYE PRESSURE USING IT
GB9711643D0 (en) *	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
US6933289B2 (en)	2003-07-01	2005-08-23	Allergan, Inc.	Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US7862552B2 (en)	2005-05-09	2011-01-04	Boston Scientific Scimed, Inc.	Medical devices for treating urological and uterine conditions
CA3198795A1 (en)	2020-11-18	2022-05-27	Jeffrey Becker	Complexing agent salt formulations of pharmaceutical compounds
WO2023225113A1 (en) *	2022-05-18	2023-11-23	Bexson Biomedical, Inc.	Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992009583A1 (en)	1990-11-30	1992-06-11	Leiras Oy	Novel pilocarpine derivatives and process for their preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS58126810A (ja) *	1981-12-24	1983-07-28	Kaken Pharmaceut Co Ltd	抗炎症眼科用液剤およびその製法
TW200402B (et) *	1990-08-13	1993-02-21	Senju Pharma Co

1993
- 1993-06-24 SE SE9302203A patent/SE501482C2/sv unknown
1994
- 1994-06-17 AU AU69731/94A patent/AU6973194A/en not_active Abandoned
- 1994-06-17 WO PCT/FI1994/000270 patent/WO1995000144A1/en not_active Ceased
- 1994-06-23 LT LTIP1970A patent/LT3525B/lt not_active IP Right Cessation
- 1994-08-18 EE EE9400040A patent/EE9400040A/et unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992009583A1 (en)	1990-11-30	1992-06-11	Leiras Oy	Novel pilocarpine derivatives and process for their preparation

Also Published As

Publication number	Publication date
LTIP1970A (en)	1995-01-31
SE9302203L (sv)	1994-12-25
EE9400040A (et)	1995-12-15
WO1995000144A1 (en)	1995-01-05
SE9302203D0 (sv)	1993-06-24
SE501482C2 (sv)	1995-02-27
AU6973194A (en)	1995-01-17

Publication	Publication Date	Title
AU2012255046B2 (en)	2017-06-15	High concentration olopatadine ophthalmic composition
Loftssona et al.	1999	Cyclodextrins in ophthalmic drug delivery
US5631297A (en)	1997-05-20	Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same
TWI833727B (zh)	2024-03-01	供每日一次用之苯並咪唑化合物的眼用組成物
JÄRVINEN et al.	1995	Sulfobutyl ether β-cyclodextrin (SBE-β-CD) in eyedrops improves the tolerability of a topically applied pilocarpine prodrug in rabbits
JP2018531292A6 (ja)	2018-12-13	インサイチュでゲルを形成する医薬製剤
JP2018531292A (ja)	2018-10-25	インサイチュでゲルを形成する医薬製剤
EA012836B1 (ru)	2009-12-30	Способ получения водорастворимых дитерпенов и их применение
LT3525B (en)	1995-11-27	Composition for ophthalmic use
AU2003276689B2 (en)	2009-04-09	Liquid stable composition of oxazaphosphorine with mesna
EP0776662A1 (fr)	1997-06-04	Compositions pharmaceutiques à base de méquitazine
JPH0616547A (ja)	1994-01-25	消炎点眼剤
US5977180A (en)	1999-11-02	Anandamide analog compositions and method of treating intraocular hypertension using same
JPH04504258A (ja)	1992-07-30	モノアシルホスホグリセリド類を使用して眼薬の角膜への浸透を増強する方法
Stefánsson et al.	1996	2-Hydroxypropyl-ß-Cyclodextrin in Eye Drops. Evaluation of Artificial Tear-Drops In Human Patients
TW201336527A (zh)	2013-09-16	具增強的穩定性之水性藥學組成物
EP4356929A1 (en)	2024-04-24	Antifibrotic formulation for ophthalmic treatment
CN1179979A (zh)	1998-04-29	含有多巴胺激动剂和环糊精的用于治疗近视的眼用组合物
LT3524B (en)	1995-11-27	Composition for ophthalmic use
WO2025040941A1 (en)	2025-02-27	Ophthalmic pharmaceutical compositions containing dorzolamide, methods for their preparation, and for their use
WO1995000143A1 (en)	1995-01-05	Composition for ophthalmic use
Stella et al.	1995	Sulfobutyl Ether b-Cyclodextrin (SBE-b-CD) in Eyedrops Improves the Tolerability of a Topically Applied Pilocarpine Prodrug in Rabbits
JPH0818991B2 (ja)	1996-02-28	男性ホルモン過剰を伴う疾患の処置剤
HK1194971B (en)	2017-02-10	High concentration olopatadine ophthalmic composition

Legal Events

Date	Code	Title	Description
1997-11-25	PC9A	Transfer of patents	Free format text: SANTEN OY,NIITTYHAANKATU 20, FIN-33720 TAMPERE,FI,971017
2000-01-25	MM9A	Lapsed patents	Effective date: 19990623